Rice University engineers have achieved a new benchmark in the design of atomically thin solar cells made of semiconducting perovskites, boosting their efficiency while retaining their ability to stand up to the environment.
First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China - read this article along with other careers information, tips and advice on BioSpace
China NMPA Approves Phase III Clinical Trial of ASC40 Combined with Bevacizumab for Treatment of Patients with Recurrent Glioblastoma Phase III trial will evaluate progression-free survival and overall survival of patients with recurrent glioblastoma Glioblastoma has an incidence rate of approximately 2.85 to 4.56 per 100,000 population per year in China, suggesting approximately 40,000 to 64,000 new cases of glioblastoma per year. More than 90% glioblastoma patients will relapse after surgery, radiation and chemotherapies This is the first Phase III trial of ASC40 as a first-in-class drug candidate targeting tumor lipid metabolism Phase II data of patients with recurrent glioblastoma have shown that the overall response rate for ASC40 plus Bevacizumab treatment was 65% including a complete response of 20% and a partial response of 45%
Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 4, 2021 /PRNewswire/ I-Mab (the Company ) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial (NCT04600817) of TJ107 (efineptakin alpha), a novel long-acting recombinant human interleukin-7 (rhIL-7), in patients with glioblastoma multiforme (GBM) in China.
The phase 2 trial is a randomized, single-blind, placebo-controlled study to evaluate the efficacy and safety of TJ107 in lymphopenic patients with newly diagnosed GBM who have been treated with standard concurrent chemoradiotherapy. The study s goal is to determine the proportion of patients with an increase in the absolute lymphocyte counts and associated clinical response after the administration of the first TJ107 dose.